Cincinnati, Ohio, US and Eindhoven,  27th of February 2025 – Our portfolio company Sirius Medical, the innovator of Surgical Marker Navigation and Mammotome, a globally recognized leader in breast care, are proud to announce an exclusive distribution agreement for the United States and Germany. This collaboration combines the extensive breast care knowledge and commercial capabilities of Mammotome with Sirius Medical’s technology and innovation.

Breast cancer remains a significant health challenge globally, highlighting the urgent need for advanced technologies to improve patient outcomes and streamline surgical procedures. The Sirius Pintuition^® System represents a major advancement in this field, offering surgeons enhanced accuracy and efficiency by replacing traditional localization methods with Surgical Marker Navigation for precise tumor excision.

“We are thrilled to partner with Mammotome in our mission to advance breast cancer care,” said Bram Schermers, Chief Executive Officer of Sirius Medical. “This collaboration will allow us to expand our footprint in critical markets and empower more surgeons with precise, efficient tools that transform patient outcomes.”

As a leading provider of innovative breast cancer diagnostic and surgical solutions, Mammotome is uniquely positioned to bring the Pintuition^® System to market, supported by a deep understanding of the needs of breast care professionals and their patients. Through this collaboration, Mammotome will leverage its extensive sales network across the United States and Germany, ensuring that healthcare facilities and surgeons have seamless access to Sirius Medical’s latest technology, along with Mammotome’s full portfolio of premium breast care products.

“The Pintuition^® System aligns with Mammotome’s commitment to bring innovative, high-quality solutions to healthcare providers and their patients,” said Mammotome Senior Vice President and Chief Commercial Officer Sarah Moore. “We’re excited to introduce thisadvanced technology to healthcare facilities and help enhance the quality of care for breast cancer patients.”

This partnership reinforces both companies’ dedication to driving progress in breast cancer treatment by providing state-of-the-art tools that facilitate optimal care. The Pintuition^® System will soon be available to an even broader network of surgical facilities, expandingaccess to advanced breast care technology. Further, this product will complement the Neoprobe^® Gamma Detection System and the HydroMARK™ Plus Breast Biopsy Site Marker, affording clinicians a suite of premium technologies for all their breast surgical needs.

About Sirius Medical

With its roots deeply embedded in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivering unsurpassed yet affordable solutions that enable precise and efficient removal of tumors. The Pintuition^® technology is simple, precise, affordable, CE-marked, and FDA-cleared. Sirius Medical is rapidly expanding with over 35,000 procedures worldwide in more than 225 centers and a global commercial network covering the USA, Western Europe, Australia, and New Zealand.

About Mammatome

At Mammotome, our expertise and compassion for breast care makes us the indispensable partner to physicians, clinicians and patients. Our drive for innovation is rivaled only by our compassion for the people we serve, from the clinicians and surgeons who demand consistently precise solutions, to the patients and families seeking peace of mind. Headquartered in Cincinnati, OH, Mammotome is proud to be a part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health. The Mammotome brand of products is sold in over 65 different countries throughout the world.